Sarepta Therapeutics (SRPT) Liabilities and Shareholders Equity (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Liabilities and Shareholders Equity of $3.2 billion for Q1 2026, down 8.27% year-over-year from $3.5 billion in Q1 2025, and down 5.1% quarter-over-quarter from $3.3 billion in Q4 2025.
Sarepta Therapeutics (SRPT) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $3.2 billion for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 8.27% year-over-year to $3.2 billion; the TTM figure through Mar 2026 stood at $13.7 billion (down 5.2% YoY), while the FY2025 annual figure was $3.3 billion, down 15.48% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $3.2 billion, down from $3.3 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $4.0 billion in Q4 2024, with the low at $3.0 billion in Q2 2022.
- The 5-year median for Liabilities and Shareholders Equity is $3.2 billion (2024), against an average of $3.3 billion.
- The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity advanced 21.4% in 2024, then decreased 15.48% in 2025.
- Sarepta Therapeutics' Liabilities and Shareholders Equity stood at $3.1 billion in 2022, then climbed by 4.35% to $3.3 billion in 2023, then advanced by 21.4% to $4.0 billion in 2024, then fell by 15.48% to $3.3 billion in 2025, then slipped by 5.1% to $3.2 billion in 2026.
- Business Quant data shows SRPT's Liabilities and Shareholders Equity at $3.2 billion in Q1 2026, $3.3 billion in Q4 2025, and $3.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | 3.19 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.19 Bn |
| Mar 31, 2026 | 3.18 Bn |
| Dec 31, 2025 | 3.35 Bn |
| Sep 30, 2025 | 3.49 Bn |
| Jun 30, 2025 | 3.68 Bn |
| Mar 31, 2025 | 3.47 Bn |
| Dec 31, 2024 | 3.96 Bn |
| Sep 30, 2024 | 3.60 Bn |
| Jun 30, 2024 | 3.42 Bn |
| Mar 31, 2024 | 3.22 Bn |
| Dec 31, 2023 | 3.26 Bn |
| Sep 30, 2023 | 3.11 Bn |
| Jun 30, 2023 | 3.13 Bn |
| Mar 31, 2023 | 3.06 Bn |
| Dec 31, 2022 | 3.13 Bn |
| Sep 30, 2022 | 3.16 Bn |
| Jun 30, 2022 | 3.00 Bn |
| Mar 31, 2022 | 3.06 Bn |
| Dec 31, 2021 | 3.15 Bn |
| Sep 30, 2021 | 2.66 Bn |